Spironolactone metabolism in normal subjects and in patients with liver cirrhosis

A. Váradi, T. Feher, L. Bodrogi, O. Koref

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The dynamic excretion of aldadiene, the principal metabolite of spironolactone with biological activity, was studied in normal subjects and patients with liver cirrhosis following administration of spironolactone. Aldadiene appeared in the three-days urine collection in around 3% of the dose. There was no significant difference in the biological half-life, calculated from the urinary pattern, and in the rate of excretion in patients with hepatopathy and hospitalized controls. Healthy volunteers without hospitalization exhibited the most rapid elimination of the metabolite. An increase of spironolactone dose enhanced the percent rate of aldadiene excretion, while the biological half-life did not change. Spironolactone decreased the rate of dehydroepiandrosterone and androsterone excretion even after a single dose. Determination of total 17-ketosteroids is of no value on evaluation of adrenal function during spironolactone therapy, due to a Zimmermann-positivity of spironolactone metabolites.

Original languageEnglish
Pages (from-to)1618-1620
Number of pages3
JournalArzneimittel-Forschung
Volume27
Issue number8
Publication statusPublished - 1977

Fingerprint

Spironolactone
Metabolism
Liver Cirrhosis
Liver
Canrenone
Metabolites
Half-Life
Androsterone
17-Ketosteroids
Urine Specimen Collection
Dehydroepiandrosterone
Bioactivity
Healthy Volunteers
Hospitalization

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Spironolactone metabolism in normal subjects and in patients with liver cirrhosis. / Váradi, A.; Feher, T.; Bodrogi, L.; Koref, O.

In: Arzneimittel-Forschung, Vol. 27, No. 8, 1977, p. 1618-1620.

Research output: Contribution to journalArticle

Váradi, A, Feher, T, Bodrogi, L & Koref, O 1977, 'Spironolactone metabolism in normal subjects and in patients with liver cirrhosis', Arzneimittel-Forschung, vol. 27, no. 8, pp. 1618-1620.
Váradi, A. ; Feher, T. ; Bodrogi, L. ; Koref, O. / Spironolactone metabolism in normal subjects and in patients with liver cirrhosis. In: Arzneimittel-Forschung. 1977 ; Vol. 27, No. 8. pp. 1618-1620.
@article{946250f73acc4448b1d3024f2ce451d6,
title = "Spironolactone metabolism in normal subjects and in patients with liver cirrhosis",
abstract = "The dynamic excretion of aldadiene, the principal metabolite of spironolactone with biological activity, was studied in normal subjects and patients with liver cirrhosis following administration of spironolactone. Aldadiene appeared in the three-days urine collection in around 3{\%} of the dose. There was no significant difference in the biological half-life, calculated from the urinary pattern, and in the rate of excretion in patients with hepatopathy and hospitalized controls. Healthy volunteers without hospitalization exhibited the most rapid elimination of the metabolite. An increase of spironolactone dose enhanced the percent rate of aldadiene excretion, while the biological half-life did not change. Spironolactone decreased the rate of dehydroepiandrosterone and androsterone excretion even after a single dose. Determination of total 17-ketosteroids is of no value on evaluation of adrenal function during spironolactone therapy, due to a Zimmermann-positivity of spironolactone metabolites.",
author = "A. V{\'a}radi and T. Feher and L. Bodrogi and O. Koref",
year = "1977",
language = "English",
volume = "27",
pages = "1618--1620",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "8",

}

TY - JOUR

T1 - Spironolactone metabolism in normal subjects and in patients with liver cirrhosis

AU - Váradi, A.

AU - Feher, T.

AU - Bodrogi, L.

AU - Koref, O.

PY - 1977

Y1 - 1977

N2 - The dynamic excretion of aldadiene, the principal metabolite of spironolactone with biological activity, was studied in normal subjects and patients with liver cirrhosis following administration of spironolactone. Aldadiene appeared in the three-days urine collection in around 3% of the dose. There was no significant difference in the biological half-life, calculated from the urinary pattern, and in the rate of excretion in patients with hepatopathy and hospitalized controls. Healthy volunteers without hospitalization exhibited the most rapid elimination of the metabolite. An increase of spironolactone dose enhanced the percent rate of aldadiene excretion, while the biological half-life did not change. Spironolactone decreased the rate of dehydroepiandrosterone and androsterone excretion even after a single dose. Determination of total 17-ketosteroids is of no value on evaluation of adrenal function during spironolactone therapy, due to a Zimmermann-positivity of spironolactone metabolites.

AB - The dynamic excretion of aldadiene, the principal metabolite of spironolactone with biological activity, was studied in normal subjects and patients with liver cirrhosis following administration of spironolactone. Aldadiene appeared in the three-days urine collection in around 3% of the dose. There was no significant difference in the biological half-life, calculated from the urinary pattern, and in the rate of excretion in patients with hepatopathy and hospitalized controls. Healthy volunteers without hospitalization exhibited the most rapid elimination of the metabolite. An increase of spironolactone dose enhanced the percent rate of aldadiene excretion, while the biological half-life did not change. Spironolactone decreased the rate of dehydroepiandrosterone and androsterone excretion even after a single dose. Determination of total 17-ketosteroids is of no value on evaluation of adrenal function during spironolactone therapy, due to a Zimmermann-positivity of spironolactone metabolites.

UR - http://www.scopus.com/inward/record.url?scp=0017725077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017725077&partnerID=8YFLogxK

M3 - Article

C2 - 578759

AN - SCOPUS:0017725077

VL - 27

SP - 1618

EP - 1620

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 8

ER -